603707 Nanjing King-Friend Biochemical Pharmaceutical
- 15.43
- +0.15+0.98%
Nanjing King-Friend Biochemical Pharmaceutical News
Jianyou Co., Ltd.: Announcement of Jianyou Co., Ltd. on the consistent evaluation of the quality and efficacy of daxaparin sodium injections as generic drugs
Announcement of Jianyou Co., Ltd. on the consistent evaluation of the quality and efficacy of daxaparin sodium injections as generic drugs
Jianyou Co., Ltd.: Announcement of Jianyou Co., Ltd. on holding a results briefing for the third quarter of 2024
Jianyou Co., Ltd.: Announcement of Resolutions of the 11th Meeting of the Fifth Board of Directors of Jianyou Co., Ltd.
Jianyou Co., Ltd.: Announcement of Jianyou Co., Ltd. on the action plan to “improve quality, increase efficiency and focus on return”
Jianyou Co., Ltd.: Jianyou Co., Ltd. 2024 Third Quarter Report.docx
Jianyou Co., Ltd. 2024 Third Quarter Report.docx
Announcement of Jianyou Co., Ltd. on the action plan to “improve quality, increase efficiency, and focus on return”
Announcement of Resolutions of the 11th Meeting of the 5th Board of Directors of Jianyou Co., Ltd.
Announcement of Jianyou Co., Ltd. on holding a results briefing for the third quarter of 2024
Announcement of Jianyou Co., Ltd. on not revising the Jianyou debt-for-share conversion price downward
Announcement of Jianyou Co., Ltd. on the approval of its subsidiary product doxycycline hydrochloride for injection from the US FDA
An indicative announcement by Jianyou Co., Ltd. regarding the “Jianyou Convertible Bonds” expected to meet the revised terms of the conversion price
Announcement of Jianyou Co., Ltd. on obtaining registration approval for injectable pantoprazole sodium from the State Drug Administration
Jianyou Co., Ltd.: Announcement of Jianyou Co., Ltd. on the “Jianyou Convertible Bonds” share conversion results and stock changes
Announcement of Jianyou Co., Ltd. on the “Jianyou Bonds” conversion results and stock changes
Announcement of Jianyou Co., Ltd. on the progress of the company\'s application for comprehensive credit lines and provision of collateral guarantees from banks
Jianyou Co., Ltd.: Announcement of Jianyou Co., Ltd. on the approval of its subsidiary product fluorouracil injection from the US FDA
Announcement of Jianyou Co., Ltd. on the approval of its subsidiary fluorouracil injection from the US FDA
Announcement of Jianyou Co., Ltd. on its subsidiary obtaining a drug registration certificate for oxaliplatin injections from the State Drug Administration
Analysis
Price Target
No Data
No Data